Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review.


Journal

Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651

Informations de publication

Date de publication:
2019
Historique:
received: 07 06 2019
accepted: 10 06 2019
pubmed: 21 6 2019
medline: 26 6 2020
entrez: 21 6 2019
Statut: ppublish

Résumé

Sarcopenia has been considered a poor prognostic factor in various malignant diseases. However, the studies that evaluated the association between CT-determined sarcopenia and outcome in breast cancer patients reported different results. Therefore, the aim of the present study is to perform a systematic review of the current literature on the evaluation of body CT-determined sarcopenia in breast cancer patients, focusing on the correlation with outcome values. Two reviewers evaluated independently all studies dealing with CT-determined sarcopenia in breast cancer women from major medical libraries up to 24 April 2019. The keywords used for database searching were: "sarcopenia" or "muscles" or "muscle weight" or "body composition" and "breast neoplasms" or "breast cancer" and "computed tomography". Studies reporting clinical outcome values were finally compared. Of the n = 191 studies identified, a total of n = 15 articles were included in the systematic review. In all studies, sarcopenia was assessed at the level of the third lumbar vertebra (L3) on CT; n = 14/15 studies were retrospective. N = 13/15 studies evaluated the impact of sarcopenia on clinical outcomes. Among these studies, n = 8/13 studies concluded that sarcopenia is an important risk factor for poor prognosis in breast cancer and n = 5/13 studies concluded that body composition changes are not associated with poor prognosis. Most studies concluded that sarcopenia assessed on CT is an important prognostic risk factor in breast cancer patients. High-quality prospective studies to strongly confirm and assess the impact of sarcopenia evaluated on CT and breast cancer outcome are needed.

Identifiants

pubmed: 31220793
pii: S2468-2942(19)30112-1
doi: 10.1016/j.ctarc.2019.100154
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100154

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Federica Rossi (F)

Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy. Electronic address: federossi0590@gmail.com.

Francesca Valdora (F)

Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.

Bianca Bignotti (B)

Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.

Lorenzo Torri (L)

Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.

Giulia Succio (G)

IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Alberto Stefano Tagliafico (AS)

Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH